Harvard Bioscience Inc expected to post a loss of 4 cents a share - Earnings Preview

Harvard Bioscience

09/05/2025 17:16

Harvard Bioscience Inc HBIO.OQ HBIO.O is expected to show a fall in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Holliston Massachusetts-based  company is expected to report a 21.7% decrease in revenue to $19.2 million from $24.51 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on March 12 2025, for the period ended March 31, was for revenue between $19.00 million and $21.00 million.

​LSEG's mean analyst estimate for Harvard Bioscience Inc is for a loss of 4 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Harvard Bioscience Inc is $4.50​, above​ its last closing price of $0.30. ​​​

The company's guidance on March 12 2025 for the period ended March 31 was for gross profit margin between USD56% and USD58%.

This summary was machine generated May 9 at 16:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)